| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| IL-7 R alpha | HOT IL7-H52H7 | Human IL-7 R alpha / CD127 Protein, His Tag, low endotoxin |  Human | HEK293 |  | SDS-PAGE | $330.00 100ug |   | |
| IL-7 R alpha | HOT IL7-H5258 | Human IL-7 R alpha / CD127 Protein (I66T, V138I), Mouse IgG2a Fc Tag | Human | HEK293 |  | SDS-PAGE | $330.00 100ug | | |
| IL-7 R alpha | HOT ILA-H525a | Human IL-7 R alpha / CD127 Protein, Fc Tag | Human | HEK293 |  | SDS-PAGE | $285.00 100ug | | |
| IL-7 R alpha | HOTAvitag IL7-H82F9 | Biotinylated Human IL-7 R alpha / CD127 Protein, Fc,Avitag™ | Human | HEK293 |  | SDS-PAGE | $380.00 25ug | | |
| IL-7 R alpha | Cynomolgus IL-7 R alpha / CD127 Protein, His Tag (MALS verified) |  Cynomolgus | HEK293 |  | MALSSDS-PAGE | $300.00 100ug | | ||
| IL-7 R alpha | Human IL-7 R alpha Protein, Mouse IgG2a Fc Tag | Human | HEK293 |  | SDS-PAGE | $336.00 100ug | | ||
| IL-7 R alpha | Mouse IL-7 R alpha / CD127 Protein, Fc Tag |  Mouse | HEK293 |  | SDS-PAGE | $330.00 100ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| CYT-107 | CYT-107; CYT-99-007; rhIL-7 | Phase 2 Clinical | Revimmune Inc | Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Catheter-Related Infections; Coronavirus Disease 2019 (COVID-19); Hepatitis B, Chronic; Hepatitis C; HIV Infections; Kidney Neoplasms; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Lymphopenia; Metastatic breast cancer; Multiple Myeloma; Mycobacterium Infections, Nontuberculous; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Sarcoma; Sarcoma, Kaposi; Sepsis; Shock, Septic; Skin Melanoma; T-Lymphocytopenia, Idiopathic CD4-Positive; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms | Details |
| Lusvertikimab | OSE-127; S-95011; Effi-7; OSE-217 | Phase 2 Clinical | Effimune | Colitis, Ulcerative; Sjogren's Syndrome | Details |
| Efineptakin alfa | TJ-107; GX-I7; NT-I7 | Phase 2 Clinical | Gannex Pharma Co Ltd | Astrocytoma; Breast Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Esophageal Neoplasms; Glioblastoma; Glioma; Gliosarcoma; HIV Infections; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Leukoencephalopathy, Progressive Multifocal; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphopenia; Melanoma; Multiple Myeloma; Oropharyngeal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Plasmablastic Lymphoma; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Kaposi; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms | Details |
| ASP-9801 | ASP-9801 | Phase 1 Clinical | Astellas Pharma Inc | Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| PF-06342674 | RN-168; PF-6342674; PF-06342674; ZB-168 | Phase 1 Clinical | Pfizer Inc | Diabetes Mellitus, Type 1; Multiple Sclerosis | Details |
| CD19-IL7Ra CAR-T cells therapy (Chulalongkorn University) | CMD-63; CMD63 | Phase 1 Clinical | Chulalongkorn University | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Loco-regional B7H3 IL-7Ra CAR T Cell therapy(Chulalongkorn University) | Phase 1 Clinical | Chulalongkorn University, King Chulalongkorn Memorial Hospital | Brain Neoplasms; Diffuse Intrinsic Pontine Glioma; Neoplasms; Solid tumours | Details | |
| MDK-703 | MDK-703 | Phase 1 Clinical | Medikine Inc | Solid tumours | Details |
